EC clears Pharming’s Joenja for APDS in Europe

Pharming said the European Commission has granted marketing authorization for Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome, or APDS, in adults and pediatric patients age 12 and older, making it the first approved treatment for the rare primary immunodeficiency in the European Union. The approval follows a positive CHMP opinion adopted on March 26, 2026, and applies across the EU, as well as Norway, Iceland, and Liechtenstein. Joenja is an oral PI3Kδ inhibitor, and Pharming has said the decision is based on clinical data showing reductions in lymphadenopathy and increases in naïve B cells in patients with APDS. (nasdaq.com)

Why it matters: While this is a human medicine approval rather than a veterinary one, it’s a notable example of how regulators are handling ultra-rare, genetically defined immune disorders and targeted therapies. For veterinary professionals, especially those following comparative immunology, translational medicine, or specialty referral trends, the decision underscores continued momentum behind precision treatments aimed at specific molecular pathways, rather than broad symptomatic management alone. It also highlights the growing regulatory acceptance of approvals in very small populations when biomarker and clinical data are aligned. (ema.europa.eu)

What to watch: Next will be country-level reimbursement, launch timing across Europe, and whether Pharming can expand access in younger children after mixed regulatory progress elsewhere, including a U.S. Complete Response Letter for ages 4 to 11 in February 2026. (live.euronext.com)